Rockville’s I-Mab, Bristol Myers Squibb to collaborate on new cancer study

I-Mab LogoI-Mab, the Rockville-based global biotech company focused on cancer treatment, Wednesday announced it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate the combination of two drugs as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers.